What’s Next for METdel14 NSCLC? - 102164


What’s Next for METdel14 NSCLC?

Description: Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute summarizes the next steps for METdel14 mutations and MET inhibitors for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
Shared By : AnnualMeeting2017
Posted on : 06/13/17
Added : 2 years ago